Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Invested Capital (2019 - 2025)

Eton Pharmaceuticals' Invested Capital history spans 7 years, with the latest figure at $25.9 million for Q3 2025.

  • For Q3 2025, Invested Capital rose 28.83% year-over-year to $25.9 million; the TTM value through Sep 2025 reached $25.9 million, up 28.83%, while the annual FY2024 figure was $54.2 million, 250.45% up from the prior year.
  • Invested Capital for Q3 2025 was $25.9 million at Eton Pharmaceuticals, down from $26.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $54.4 million in Q1 2025 and bottomed at $15.5 million in Q4 2023.
  • The 5-year median for Invested Capital is $21.1 million (2023), against an average of $24.6 million.
  • The largest annual shift saw Invested Capital decreased 28.93% in 2022 before it skyrocketed 250.45% in 2024.
  • A 5-year view of Invested Capital shows it stood at $22.9 million in 2021, then fell by 19.35% to $18.5 million in 2022, then dropped by 16.17% to $15.5 million in 2023, then surged by 250.45% to $54.2 million in 2024, then plummeted by 52.24% to $25.9 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Invested Capital are $25.9 million (Q3 2025), $26.7 million (Q2 2025), and $54.4 million (Q1 2025).